Clinical implications of antibiotic-induced endotoxin release in septic shock

Intensive Care Medicine

Volumn 28, Issue 7, 2002, Pages 824-833

  Lepper, P ^a   Held, T ^b   Schneider, E ^a   Bolke E ^a   Gerlach, H ^b   Trautmann, M ^a,c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c KATHARINENHOSPITAL   (Germany)

Author keywords

Antibiotic therapy; Endotoxin; Induced endotoxaemia; Sepsis; Septic shock syndrome; TLR4; TNF

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; ENDOTOXIN; ANTIINFECTIVE AGENT; LACTAM; LIPOPOLYSACCHARIDE;

BACTERIAL CELL WALL; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; MYCOSIS; NONHUMAN; PATHOGENESIS; REVIEW; SEPSIS; SEPTIC SHOCK; ANIMAL; BODY FLUID; CHEMICALLY INDUCED DISORDER; GERMANY; GRAM NEGATIVE BACTERIUM; METABOLISM; TREATMENT OUTCOME;

ANIMAL; ANTIBIOTICS, LACTAM; BODY FLUIDS; GERMANY; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; LIPOPOLYSACCHARIDES; SHOCK, SEPTIC; TREATMENT OUTCOME; ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; LACTAMS;

EID: 0036020289     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1330-6     Document Type: Review

References (102)

1. From the centers for disease control. Increase in national hospital discharge survey rates for septicemia-United States, 1979-1987
2. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM- enriched product
3. Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are opsonic and protect mice against lethal challenge
4. The cytokine network in the critically ill
5. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome
6. Mediators of multiple organ failure
7. Stimulation of monokine production by lipoteichoic acids
8. 39 is critical for the recognition of Staphylococcus aureus peptidoglycan
9. Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria: Effects of antibiotic treatment
10. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes
11. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6
12. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans
13. Structures in Bacillus subtilis are recognized by CD14 in a lipopolysaccharide binding protein-dependent reaction
14. Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures
15. Lipopolysaccharide and mono-phosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages
16. Clinical relevance of antibiotic-induced endotoxin release
17. Endotoxin signal transduction in macrophages
18. Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: A short review
19. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria
20. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins
21. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells
22. A conserved signaling pathway: The Drosophila toll-dorsal pathway
23. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components
24. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans
25. Intravenous immunoglobulins inhibit LPS-induced TNF-alpha release from human monocytic cells
26. Cutting edge: Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2
27. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors
28. The NF-kappa B and I kappa B proteins: New discoveries and insights
29. Lipopolysaccharide-triggered desensitization of TNF-alpha mRNA expression involves lack of phosphorylation of I kappa B alpha in a murine macrophage-like cell line, P388D1
30. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis
31. Tumor necrosis factor in the heart
32. Cardiac surgical implications of calcium dyshomeostasis in the heart
33. Evolution and phylogeny of defense molecules associated with innate immunity in horseshoe crab
34. New types of clotting factors and defense molecules found in horseshoe crab hemolymph: Their structures and functions
35. The history of the development of the Limulus amebocyte lysate test
36. The Limulus amebocyte lysate test: Perspectives and problems
37. Endotoxin shedding by enterobacteria: Free and cell-bound endotoxin differ in Limulus activity
38. The role of antimicrobial peptides in animal defenses
39. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide)
40. Neutralization of bacterial lipopolysaccharides by human plasma
41. Experimental Gram-negative bacterial sepsis: Reevaluation of the ability of rough mutant antisera to protect mice
42. Jarisch-Herxheimer reaction in early syphilis: Treatment with crystaline penicillin G
43. Activation of protein mediators of inflammation and evidence for endotoxemia in Borrelia recurrentis infection
44. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha
45. Cytokines involved in human septic shock - The model of the Jarisch-Herxheimer reaction
46. Induction of proinflammatory responses in human monocytes by particulate and soluble forms of lipopolysaccharide
47. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes
48. Antibiotic-induced release of endotoxin: A reappraisal
49. β-Lactam antibiotic-induced release of free endotoxin: In vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime
50. Kinetics of endotoxin release during antibiotic therapy for experimental Gram-negative bacterial sepsis
51. Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: The effect of antibiotic administration
52. Protective effect of subinhibitory polymyxin B alone and in combination with ampicillin for overwhelming Haemophilus influenzae type B infection in the infant rat: Evidence for in vivo and in vitro release of free endotoxin after ampicillin treatment
53. Effect of polymyxin B sulfate on endotoxin activity in a Gram-negative septicemia model
54. Bactericidal activity of beta-lactams and amikacin against Haemophilus influenzae: Effect on endotoxin release
55. Effects of different types and combinations of antimicrobial agents on endotoxin release from Gram-negative bacteria: An in-vitro and in-vivo study
56. Antibiotic-induced release of endotoxin in chronically bacteriuric patients
57. Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative bacterial sepsis
58. Acute bacterial meningitis in the newborn
59. Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis
60. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988
61. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: Influence of antibiotic class, antibiotic concentration, and presence of septic serum
62. Differential antibiotic-induced release of endotoxin from Gram-negative bacteria
63. The response of Enterobacteriaceae to beta-lactam antibiotics - 'Round forms, filaments, and the root of all evil'
64. Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: Delay between killing by ceftazidime and imipenem and release of LPS
65. Antibiotic-induced release of endotoxin: In vitro comparison of meropenem and other antibiotics
66. Antibiotic-induced endotoxin release in patients with Gram-negative urosepsis: A double-blind study comparing imipenem and ceftazidime
67. Target for bacteriostatic and bactericidal activities of beta-lactam antibiotics against Escherichia coli resides in different penicillin- binding proteins
68. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects
69. Antibiotic-induced endotoxin release
70. Postantibiotic effect of beta-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP
71. Relation of structural properties of beta-lactam antibiotics to antibacterial activity
72. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: A review
73. Reappraisal of the role of endotoxin in the sepsis syndrome
74. Penicillin-binding proteins of Gram-negative bacteria
75. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329
76. Interplay of impermeability and chromosomal beta-lactamase activity in Imipenem-resistant Pseudomonas aeruginosa
77. Imipenem-induced resistance to anti-pseudomonadal beta-lactams in Pseudomonas aeruginosa
78. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins
79. Protection from endo-toxemia: A rat model of plasmapheresis and specific adsorption with polymyxin B
80. Inactivation of endotoxin by polymyxin B
81. Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate
82. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide
83. Release of endotoxin from Escherichia coli by quinolones
84. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release
85. Inhibition of endotoxin reactivity by aminoglycosides
86. Aminoglycosides modify the in vitro metachromatic reaction and murine generalized Shwartzman phenomenon induced by Salmonella minnesota R595 lipopolysaccharide
87. Endotoxin release due to ciprofloxacin measured by three different methods
88. Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNF alpha) production and TNF alpha-mRNA accumulation in human blood monocytes
89. Teicoplanin reduces in-vitro reactivity and murine lethality of Salmonella minnesota R595 lipopolysaccharide
90. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of Gram-negative sepsis
91. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli
92. Antibiotic-induced endotoxin release from bacteria and its clinical significance
93. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients
94. Differential antibiotic-induced endotoxin release in severe melioidosis
95. Dynamics of blood cytokine concentrations in patients with bacteremic infections
96. The clinical significance of positive blood cultures: A comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis
97. Treating patients with severe sepsis
98. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome
99. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
100. The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever
101. Sepsis and serum cytokine concentrations
102. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin